Tilray Broadens UK Medical-Product Distribution Through New Alliance

Tilray is advancing its European medical strategy in the United Kingdom by linking CC Pharma with Smartway Pharmaceuticals to expand the supply of parallel imports and specialty pharmaceuticals nationwide. The plan centers on a market segment the company values at nearly ?1 billion, leveraging existing routes into the UK health system. The collaboration has roots dating back to 2009.

Key details at a glance:
- Partners: CC Pharma (Tilray) and Smartway Pharmaceuticals
- Focus: Parallel imports and specialty pharmaceuticals for pharmacies and hospitals
- Target market: United Kingdom
- Market size as estimated by Tilray: nearly £1 billion (parallel imports/specialty segment)
- Working relationship: In place since 2009

What the agreement covers
Tilray announced that CC Pharma has forged a strategic arrangement with the UK distributor Smartway Pharmaceuticals to broaden nationwide supply in both parallel-import channels and the provision of specialty medicines. Each party contributes distinct strengths: CC Pharma brings European sourcing and GMP capabilities, while Smartway supplies an established national distribution network capable of delivering products to pharmacies and hospitals across the UK.

Why the United Kingdom matters for Tilray
Rajnish Ohri, Tilray?s President of International, underscored that the UK is a priority market within the company?s global medical strategy. The deal is designed to deepen Tilray?s access to the UK?s distribution channels within the National Health Service framework and could pave the way for bringing its own licensed medical cannabis products through these channels.

The partnership builds on a preexisting relationship: both firms indicate a collaboration history since 2009 in cross-border pharmaceutical operations and supply-chain initiatives.

Context and recent developments
Tilray aims to bolster supply reliability and extend its reach through Smartway?s network, with the parallel-import and specialty segment estimated at about £1 billion. The news follows several recent company updates: in early February CC Pharma was recognized in Germany as a TOP 100 Innovator. In January, Tilray reported for the second quarter of fiscal year 2026 net revenue of $218 million, and its international medical cannabis revenue rose 36% year over year.